Stock News

Biogen in up to $1.8 billion deal as rare diseases take center stage
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
UPDATE 1-Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
15 Most Depressed States in the US

As seen on...